Fibrosis-4指数有助于识别肝细胞癌风险最低的HBV携带者
在2075例未治疗、基线无肝硬化的台湾慢性HBV感染者中平均随访16.02年,基线FIB-4>1.29者HCC风险高于FIB-4<1.29者(HR 5.56,95%CI 3.93-7.86)。在532例接受长期核苷(酸)类似物治疗且病毒复制受抑的非肝硬化患者中验证,FIB-4<1.29者HCC风险持续最低。
要点
- 基线FIB-4>1.29的未治疗慢性HBV感染者HCC风险高于FIB-4<1.29者(HR 5.56,95%CI 3.93-7.86)。
- 低病毒载量(HBV DNA<2,000 IU/ml)且HBeAg阴性、FIB-4<1.29、ALT<40 U/l、HBsAg<1,000 IU/ml的326例患者无一发生HCC。
- 接受长期NUC治疗且病毒复制受抑的非肝硬化患者中,FIB-4<1.29者HCC风险持续最低。
核心结论
- 在非肝硬化慢性HBV感染者中,FIB-4指数<1.29可补充现有临床特征以界定HCC风险最低的患者。
研究设计与样本
- 研究纳入2075例未治疗、基线无肝硬化的台湾慢性HBV感染者,平均随访16.02年。
- 在532例接受长期核苷(酸)类似物治疗且病毒复制受抑的非肝硬化患者中验证。
主要发现
- 未治疗队列中137例发生HCC,NUC治疗验证队列中10例发生HCC。
- 未治疗队列中基线FIB-4>1.29者HCC风险高于FIB-4<1.29者,HR为5.56(95%CI 3.93-7.86)。
- 低病毒载量(HBV DNA<2,000 IU/ml)患者中,326例HBeAg阴性且FIB-4<1.29、ALT<40 U/l、HBsAg<1,000 IU/ml者无一发生HCC。
- 验证队列中FIB-4<1.29者HCC风险持续最低。
关键数值与推荐
- 基线FIB-4指数阈值1.29用于区分HCC风险。
- 低病毒载量定义为HBV DNA<2,000 IU/ml;ALT阈值<40 U/l;HBsAg阈值<1,000 IU/ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Several viral and host risk factors have been used to predict risks of hepatocellular carcinoma (HCC) in patients with chronic infection of hepatitis B virus (HBV). However, little is known whether fibrosis-4 (FIB-4) index, a liver fibrosis biomarker, helps identify non-cirrhotic patients with the lowest HCC risk. METHODS: A total of 2075 treatment-naive Taiwanese patients with chronic HBV infection were followed for an average period of 16.02 years. None of them had liver cirrhosis at baseline. We explored whether a low FIB-4 index complements the favourable predictors to defines patients with the lowest HCC risk. The finding was validated in 532 non-cirrhotic patients receiving long-term nucleos(t)ide analogue (NUC) treatment with suppressed viral replication. RESULTS: A total of 137 treatment-naive and 10 NUC-treated patients developed HCC, respectively. We found that HCC risk started to increase when baseline FIB-4 index >1.29 in the treatment-naive cohort. Patients with FIB-4 >1.29, compared to those with FIB-4 <1.29, were associated with a higher risk of HCC with hazards ratio of 5.56 (95% confidence interval: 3.93-7.86). More importantly, among patients with low viral load (HBV DNA level <2,000 IU/ml), baseline FIB-4 index helped stratify different HCC risks such that none of 326 HBeAg-negative patients with FIB-4 index <1.29, ALT level <40 U/l, and HBsAg level <1,000 IU/ml developed HCC. In addition, the patients with the FIB-4 index <1.29 consistently had the lowest HCC risks in the validation cohort receiving long-term NUC treatment. CONCLUSIONS: In non-cirrhotic patients with chronic HBV infection, FIB-4 index <1.29 complements the existing clinical profile to define patients with the lowest HCC risk.
引用
- Tseng TC, Liu CJ, Su TH, et al. Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma. Am J Gastroenterol. 2017. PMID: 28853728. doi:10.1038/ajg.2017.254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。